Developer docs
API playgroundTry for free, no card

Search company profiles

Virscio

Full company profile

uuid0008x2h

Namestring
Virscio
Legal namestring
Virscio, Inc.
Websiteurl
virscio.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Virscio is a specialty contract research organization (CRO) that provides preclinical and translational research services for therapeutic development across CNS, ophthalmology, cardiovascular, metabolic, and gene/cell therapy indications. Founded in 2002 and co-led by Matthew Lawrence, MD/PhD (CEO/CSO) and Christopher Stanley (CBO/CFO), the company serves global pharmaceutical companies, venture-backed biotechnology companies, and academic and government research institutions through formal RFP-based engagements. Its core customer problems are the translational gap between rodent preclinical models and human clinical outcomes, restricted NHP supply at incumbent CROs, and the high cost and timeline of IND-enabling programs.

The company's technical platform is built around three integrated cores: an in vivo nonhuman primate (NHP) vivarium in St. Kitts, West Indies, populated by African green monkeys sourced from a unique island population of 35,000+ animals and managed through a direct partnership with the St. Kitts government; a digital histopathology and tissue pharmacodynamics core in New Haven, CT, featuring AI-enabled image analysis (Visiopharm), immunohistochemistry, and pathology interpretation; and a molecular biology core offering qPCR/ddPCR, ELISA, RNA-Seq, single-cell sequencing, and western blots. The St. Kitts green monkey is the central asset — it is biologically clean (low AAV neutralizing antibody prevalence, free of continental NHP zoonoses), evolutionarily close to humans, and materially cheaper (~1/3) than cynomolgus macaques. Virscio has 30+ validated disease models, GLP compliance since 2008, AAALAC accreditation since 2010, and 60+ peer-reviewed publications in journals including Nature and Science Translational Medicine.

Virscio generates revenue through fee-for-service contract research, with multi-year engagements spanning early proof-of-concept studies through GLP-compliant IND-enabling toxicology, safety pharmacology, biodistribution, and efficacy studies. Go-to-market is direct enterprise field sales led by the CBO and business development team, augmented by a "no-risk engagement model" that provides study design and budget preparation at no cost to prospective clients. The company does not publicly disclose pricing, operates with no channel partners or resellers, and serves a globally distributed client base from its two facilities in New Haven, CT and St. Kitts. The launch of its Pathology and Tissue Pharmacodynamics Services Division in 2025 expanded the platform beyond in vivo services into integrated histology and image analysis.

Short descriptiontext

Virscio is a specialty contract research organization providing preclinical translational research services using African green monkeys from St. Kitts. It serves biotech, pharmaceutical, and academic clients worldwide with integrated in vivo, digital histopathology, and molecular biology capabilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNew Haven, United States
HQ citystring
New Haven
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical CRO services, nonhuman primate research, GLP toxicology studies, translational research services, gene therapy preclinical
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Preclinical Contract Research Services
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services (CRO)
TypeProfessional Services
Description

Virscio operates as a specialty contract research organization (CRO) providing preclinical and translational research services. Revenue is generated through fee-for-service contracts for study design, execution, sample processing, data analysis, and reporting. Engagements range from early proof-of-concept studies to GLP-compliant IND-enabling studies. Clients include biotech, pharma, and academic institutions worldwide.

virscio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Others
Pricing details1 tier
1Custom Contract Research Services - pricing determined by study scope, complexity, duration, and animal count
ModelOtherBilling cadenceMulti-year contract
Notes

As a specialty CRO, Virscio provides custom study quotes based on protocol design, animal procurement, study duration, endpoints, and regulatory requirements. No standardized pricing tiers are publicly available. The company explicitly offers study design and budget preparation at no cost to prospective clients.

virscio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Virscio is a specialty contract research organization that provides preclinical and translational research services using African green monkeys (nonhuman primates from St. Kitts), supported by integrated digital histopathology with AI-enabled image analysis and molecular biology services. The company designs and executes GLP-compliant IND-enabling studies, efficacy studies, safety pharmacology, biodistribution, and pharmacokinetic/pharmacodynamic studies for biotech, pharmaceutical, and academic clients worldwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Enrolling a naive St. Kitts green monkey costs approximately 1/3 the cost of a cynomolgus monkey, translating into significantly lower overall study costs
+3 more records
Product overview1 text field

Virscio is a specialty translational research organization providing preclinical and translational research services, in vivo nonhuman primate disease modeling, and related histopathology services. The company operates a fully integrated platform combining in vivo NHP research services (using African green monkeys from St. Kitts), digital histopathology and histomolecular services, and molecular biology services. Core service areas include GLP toxicology, safety pharmacology, gene and cell therapy services, and CNS/translational research. The company maintains specialized expertise across therapeutic areas including CNS, ophthalmology, cardiovascular, metabolic, immunology, and gene/cell therapy, with operations in New Haven, CT and St. Kitts, West Indies.

Product and service13 records
1Nonhuman Primate Research Services
CategoryPreclinical CRO Services
Description

In vivo preclinical research services using African green monkeys (St. Kitts green monkeys) for therapeutic development, including pharmacokinetics, pharmacodynamics, efficacy studies, and safety evaluation for biotech, pharmaceutical, and academic clients.

2Digital Histopathology Services
CategoryHistopathology and Tissue Analysis Services
Description

Digital histopathology and histomolecular core supporting all tissue types and species (mouse to nonhuman primate and human), including discovery histopathology, toxicologic histopathology, and tissue pharmacodynamics with AI-enabled image analysis.

3Molecular Biology Services
CategoryMolecular Biology Research Services
Description

Molecular biology services providing mechanistic insights into disease model pathophysiology and tissue pharmacodynamics of interventions, including custom method development, biodistribution assays (qPCR, ddPCR), gene expression profiling (RNA-Seq, single cell sequencing), and western blots.

4GLP Toxicology Services
CategoryGLP Toxicology
Description

GLP-compliant toxicology services from preclinical proof-of-concept to IND-enabling studies, supporting delivery and distribution, pharmacokinetics and pharmacodynamics, efficacy, and exploratory safety assessments.

5Safety Pharmacology Services
CategorySafety Pharmacology
Description

Cardiovascular safety pharmacology and pharmacodynamic research including ECG, blood pressure, heart rate measurements, echocardiography, and telemetry for preclinical to IND-enabling studies.

6Gene and Cell Therapy Services
CategoryGene and Cell Therapy Research
Description

Comprehensive gene and cell therapy services from preclinical proof-of-concept to IND-enabling studies, including pharmacokinetics, pharmacodynamics, delivery optimization, safety pharmacology, and biodistribution determinations.

7CNS Translational Research Services
CategoryCNS Disease Modeling
Description

Central nervous system research services using nonhuman primates with validated test systems for proof-of-concept and candidate screening, including disease modeling for Alzheimer's, Parkinson's, stroke, and spinal cord injury.

8Pathology and Tissue Pharmacodynamics Services Division
CategoryPathology Services
Description

Newly launched Pathology and Tissue Pharmacodynamics Services Division offering tissue processing, slide preparation, staining, immunohistochemistry, digital slide scanning, quantitative image analysis, and pathology interpretation across GLP, non-GLP, and GCLP studies.

9VEGF-Induced Retinal Vascular Leakage Model
CategoryOphthalmology Disease Model
Description

Preclinical ophthalmology model for evaluating treatments targeting retinal vascular diseases using VEGF-induced retinal vascular permeability assessment in nonhuman primates.

10Laser-Induced CNV Models
CategoryOphthalmology Disease Model
Description

Ophthalmology disease models for age-related macular degeneration using laser-induced choroidal neovascularization for efficacy studies of anti-neovascular agents in nonhuman primates.

11Intraocular Pressure Lowering Research
CategoryOphthalmology Disease Model
Description

Glaucoma research services evaluating intraocular pressure modulation candidates using validated primate models and clinical instrumentation.

12Ocular Inflammation Research Model
CategoryOphthalmology Disease Model
Description

Anterior uveitis model induced by intracameral concanavalin A administration for evaluating anti-inflammatory agents and efficacy of test compounds in nonhuman primates.

13Laser-Induced Glaucoma Model
CategoryOphthalmology Disease Model
Description

Chronic ocular hypertension model using laser scarification for evaluating IOP-lowering and neuroprotective agents with RNFL, optic nerve head, and neuroretina assessments in nonhuman primates.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1St. Kitts Government (Ministry of Agriculture)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Virscio has a direct government partnership with the St. Kitts government to humanely manage the African green monkey population on the island. This partnership enables sustainable access to a large, biologically clean NHP population for in vivo research. The population of 60,000+ monkeys presents an ecological and agricultural threat, and Virscio's research use serves as a humane population control mechanism while generating critical biomedical data.

virscio.com
2Specialty Third-Party Laboratories and Consultants
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Virscio regularly works with qualified specialty laboratories and consultants to execute elements of research plans not conducted directly by Virscio. Site or consultant qualification is performed by Virscio's senior scientists and quality assurance unit. Specimen shipment for analysis at third-party or sponsor laboratories is supported through temperature-controlled chain of custody with full tracking.

virscio.com
3UCLA Brain Research Center / Brain Atlas Project
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Virscio leverages the publicly available Green Monkey Brain Atlas developed by UCLA's Brain Research Center, along with the reference genome (Ensembl Green Monkey Browser) and systems biology resources. These databases inform model characterization and cross-species comparative biology.

virscio.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers6 records
TypeBroad incumbent
Description

Charles River is the largest preclinical CRO globally with extensive NHP vivarium capacity and Research Models & Services, Safety Assessment, and Discovery & Safety Assessment segments. It is a broad incumbent in the same preclinical CRO space as Virscio, with overlapping GLP toxicology, safety pharmacology, and NHP services but a much larger global footprint and broader service menu.

TypeDirect peer
Description

Inotiv is a pure-play preclinical CRO and research models provider with NHP services and contract research capabilities spanning toxicology, safety assessment, and disease modeling. It is a direct peer to Virscio as a specialty preclinical CRO serving biotech and pharma clients with NHP-dependent study offerings.

TypeBroad incumbent
Description

Labcorp Drug Development (formerly Covance) is a top-tier global CRO offering preclinical and clinical services including extensive NHP toxicology and safety assessment. It is a broad incumbent competitor for large pharma preclinical contracts where Virscio's smaller scale and single-island footprint may be limiting.

TypeBroad incumbent
Description

Wuxi AppTec is a major global CRO/CDMO with significant preclinical research services including NHP-based toxicology and safety assessment. It is a broad incumbent with overlapping preclinical capabilities, particularly for biotech and pharma clients in the US and Asia.

TypeBroad incumbent
Description

IQVIA is a leading global CRO with preclinical and clinical research services, including laboratory and safety assessment capabilities. It is a broad incumbent competitor for enterprise pharma CRO contracts, though its preclinical NHP footprint is more limited relative to its clinical research scale.

TypeDirect peer
Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Virscio

Preclinical Contract Research Servicesvirscio.com

Virscio is a specialty contract research organization providing preclinical translational research services using African green monkeys from St. Kitts. It serves biotech, pharmaceutical, and academic clients worldwide with integrated in vivo, digital histopathology, and molecular biology capabilities.

What Virscio does

Virscio is a specialty contract research organization (CRO) that provides preclinical and translational research services for therapeutic development across CNS, ophthalmology, cardiovascular, metabolic, and gene/cell therapy indications. Founded in 2002 and co-led by Matthew Lawrence, MD/PhD (CEO/CSO) and Christopher Stanley (CBO/CFO), the company serves global pharmaceutical companies, venture-backed biotechnology companies, and academic and government research institutions through formal RFP-based engagements. Its core customer problems are the translational gap between rodent preclinical models and human clinical outcomes, restricted NHP supply at incumbent CROs, and the high cost and timeline of IND-enabling programs.

The company's technical platform is built around three integrated cores: an in vivo nonhuman primate (NHP) vivarium in St. Kitts, West Indies, populated by African green monkeys sourced from a unique island population of 35,000+ animals and managed through a direct partnership with the St. Kitts government; a digital histopathology and tissue pharmacodynamics core in New Haven, CT, featuring AI-enabled image analysis (Visiopharm), immunohistochemistry, and pathology interpretation; and a molecular biology core offering qPCR/ddPCR, ELISA, RNA-Seq, single-cell sequencing, and western blots. The St. Kitts green monkey is the central asset — it is biologically clean (low AAV neutralizing antibody prevalence, free of continental NHP zoonoses), evolutionarily close to humans, and materially cheaper (~1/3) than cynomolgus macaques. Virscio has 30+ validated disease models, GLP compliance since 2008, AAALAC accreditation since 2010, and 60+ peer-reviewed publications in journals including Nature and Science Translational Medicine.

Virscio generates revenue through fee-for-service contract research, with multi-year engagements spanning early proof-of-concept studies through GLP-compliant IND-enabling toxicology, safety pharmacology, biodistribution, and efficacy studies. Go-to-market is direct enterprise field sales led by the CBO and business development team, augmented by a "no-risk engagement model" that provides study design and budget preparation at no cost to prospective clients. The company does not publicly disclose pricing, operates with no channel partners or resellers, and serves a globally distributed client base from its two facilities in New Haven, CT and St. Kitts. The launch of its Pathology and Tissue Pharmacodynamics Services Division in 2025 expanded the platform beyond in vivo services into integrated histology and image analysis.

Virscio firmographics

Firmographics
Name
Virscio
Legal name
Virscio, Inc.
Website
https://virscio.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
51–100 employees
Short description
Virscio is a specialty contract research organization providing preclinical translational research services using African green monkeys from St. Kitts. It serves biotech, pharmaceutical, and academic clients worldwide with integrated in vivo, digital histopathology, and molecular biology capabilities.
Ownership category
akta.pro rank

Where Virscio is headquartered

Location

Headquarters

HQ city
New Haven
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Virscio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Others

Revenue model

  1. Contract Research Services (CRO): Virscio operates as a specialty contract research organization (CRO) providing preclinical and translational research services. Revenue is generated through fee-for-service contracts for study design, execution, sample processing, data analysis, and reporting. Engagements range from early proof-of-concept studies to GLP-compliant IND-enabling studies. Clients include biotech, pharma, and academic institutions worldwide.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Contract Research Services - pricing determined by study scope, complexity, duration, and animal count

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Virscio product offering

Product offering

Core offering

Virscio is a specialty contract research organization that provides preclinical and translational research services using African green monkeys (nonhuman primates from St. Kitts), supported by integrated digital histopathology with AI-enabled image analysis and molecular biology services. The company designs and executes GLP-compliant IND-enabling studies, efficacy studies, safety pharmacology, biodistribution, and pharmacokinetic/pharmacodynamic studies for biotech, pharmaceutical, and academic clients worldwide.

Product overview

Virscio is a specialty translational research organization providing preclinical and translational research services, in vivo nonhuman primate disease modeling, and related histopathology services. The company operates a fully integrated platform combining in vivo NHP research services (using African green monkeys from St. Kitts), digital histopathology and histomolecular services, and molecular biology services. Core service areas include GLP toxicology, safety pharmacology, gene and cell therapy services, and CNS/translational research. The company maintains specialized expertise across therapeutic areas including CNS, ophthalmology, cardiovascular, metabolic, immunology, and gene/cell therapy, with operations in New Haven, CT and St. Kitts, West Indies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nonhuman Primate Research Services In vivo preclinical research services using African green monkeys (St. Kitts green monkeys) for therapeutic development, including pharmacokinetics, pharmacodynamics, efficacy studies, and safety evaluation for biotech, pharmaceutical, and academic clients.
  • Digital Histopathology Services Digital histopathology and histomolecular core supporting all tissue types and species (mouse to nonhuman primate and human), including discovery histopathology, toxicologic histopathology, and tissue pharmacodynamics with AI-enabled image analysis.
  • Molecular Biology Services Molecular biology services providing mechanistic insights into disease model pathophysiology and tissue pharmacodynamics of interventions, including custom method development, biodistribution assays (qPCR, ddPCR), gene expression profiling (RNA-Seq, single cell sequencing), and western blots.
  • GLP Toxicology Services GLP-compliant toxicology services from preclinical proof-of-concept to IND-enabling studies, supporting delivery and distribution, pharmacokinetics and pharmacodynamics, efficacy, and exploratory safety assessments.
  • Safety Pharmacology Services Cardiovascular safety pharmacology and pharmacodynamic research including ECG, blood pressure, heart rate measurements, echocardiography, and telemetry for preclinical to IND-enabling studies.
  • Gene and Cell Therapy Services Comprehensive gene and cell therapy services from preclinical proof-of-concept to IND-enabling studies, including pharmacokinetics, pharmacodynamics, delivery optimization, safety pharmacology, and biodistribution determinations.
  • CNS Translational Research Services Central nervous system research services using nonhuman primates with validated test systems for proof-of-concept and candidate screening, including disease modeling for Alzheimer's, Parkinson's, stroke, and spinal cord injury.
  • Pathology and Tissue Pharmacodynamics Services Division Newly launched Pathology and Tissue Pharmacodynamics Services Division offering tissue processing, slide preparation, staining, immunohistochemistry, digital slide scanning, quantitative image analysis, and pathology interpretation across GLP, non-GLP, and GCLP studies.
  • VEGF-Induced Retinal Vascular Leakage Model Preclinical ophthalmology model for evaluating treatments targeting retinal vascular diseases using VEGF-induced retinal vascular permeability assessment in nonhuman primates.
  • Laser-Induced CNV Models Ophthalmology disease models for age-related macular degeneration using laser-induced choroidal neovascularization for efficacy studies of anti-neovascular agents in nonhuman primates.
  • Intraocular Pressure Lowering Research Glaucoma research services evaluating intraocular pressure modulation candidates using validated primate models and clinical instrumentation.
  • Ocular Inflammation Research Model Anterior uveitis model induced by intracameral concanavalin A administration for evaluating anti-inflammatory agents and efficacy of test compounds in nonhuman primates.
  • Laser-Induced Glaucoma Model Chronic ocular hypertension model using laser scarification for evaluating IOP-lowering and neuroprotective agents with RNFL, optic nerve head, and neuroretina assessments in nonhuman primates.

Quantifiable outcome

  • Enrolling a naive St. Kitts green monkey costs approximately 1/3 the cost of a cynomolgus monkey, translating into significantly lower overall study costs
  • +3 more outcomes

Companies that use Virscio

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Virscio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Virscio partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • St. Kitts Government (Ministry of Agriculture)coreStrategic or Co-development PartnerVirscio has a direct government partnership with the St. Kitts government to humanely manage the African green monkey population on the island. This partnership enables sustainable access to a large, biologically clean NHP population for in vivo research. The population of 60,000+ monkeys presents an ecological and agricultural threat, and Virscio's research use serves as a humane population control mechanism while generating critical biomedical data.
  • Specialty Third-Party Laboratories and ConsultantsminorImplementation/ SI/ Consulting PartnerVirscio regularly works with qualified specialty laboratories and consultants to execute elements of research plans not conducted directly by Virscio. Site or consultant qualification is performed by Virscio's senior scientists and quality assurance unit. Specimen shipment for analysis at third-party or sponsor laboratories is supported through temperature-controlled chain of custody with full tracking.
  • UCLA Brain Research Center / Brain Atlas ProjectminorStrategic or Co-development PartnerVirscio leverages the publicly available Green Monkey Brain Atlas developed by UCLA's Brain Research Center, along with the reference genome (Ensembl Green Monkey Browser) and systems biology resources. These databases inform model characterization and cross-species comparative biology.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Virscio competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Charles River is the largest preclinical CRO globally with extensive NHP vivarium capacity and Research Models & Services, Safety Assessment, and Discovery & Safety Assessment segments. It is a broad incumbent in the same preclinical CRO space as Virscio, with overlapping GLP toxicology, safety pharmacology, and NHP services but a much larger global footprint and broader service menu.
  • Labcorp (Drug Development / Covance): Labcorp Drug Development (formerly Covance) is a top-tier global CRO offering preclinical and clinical services including extensive NHP toxicology and safety assessment. It is a broad incumbent competitor for large pharma preclinical contracts where Virscio's smaller scale and single-island footprint may be limiting.
  • Wuxi AppTec: Wuxi AppTec is a major global CRO/CDMO with significant preclinical research services including NHP-based toxicology and safety assessment. It is a broad incumbent with overlapping preclinical capabilities, particularly for biotech and pharma clients in the US and Asia.
  • IQVIA: IQVIA is a leading global CRO with preclinical and clinical research services, including laboratory and safety assessment capabilities. It is a broad incumbent competitor for enterprise pharma CRO contracts, though its preclinical NHP footprint is more limited relative to its clinical research scale.

Direct peers

  • Inotiv: Inotiv is a pure-play preclinical CRO and research models provider with NHP services and contract research capabilities spanning toxicology, safety assessment, and disease modeling. It is a direct peer to Virscio as a specialty preclinical CRO serving biotech and pharma clients with NHP-dependent study offerings.
  • Altasciences:

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Virscio compliance and trust

Trust signal

Compliance3 records

Virscio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Virscio leadership team

Management profile

Number of profiles

Profiles4 records

Virscio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Virscio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virscio

What does Virscio do?

Virscio is a specialty contract research organization that provides preclinical and translational research services using African green monkeys (nonhuman primates from St. Kitts), supported by integrated digital histopathology with AI-enabled image analysis and molecular biology services. The company designs and executes GLP-compliant IND-enabling studies, efficacy studies, safety pharmacology, biodistribution, and pharmacokinetic/pharmacodynamic studies for biotech, pharmaceutical, and academic clients worldwide.

Is Virscio a public or private company?

Virscio is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Virscio founded?

Virscio was founded in 2002. It employs 51 to 100 people.

Where is Virscio based?

Virscio is headquartered in New Haven, United States, in the North America region.

How does Virscio make money?

One revenue line is on record: contract Research Services (CRO).

Who are Virscio's main competitors?

Broad incumbents on record are Charles River Laboratories, Labcorp (Drug Development / Covance), Wuxi AppTec and IQVIA. Direct peers are Inotiv and Altasciences.

Does Virscio have an API?

No public API is recorded for Virscio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
VirscioInnovative Preclinical Research SolutionsVirscio is a provider of preclinical and IND-enabling research solutions, offering services such as disease model development, pharmacokinetics studies, and toxicological assessments. The company highlights its extensive experience with over 250 studies completed and more than 60 therapeutic models to support drug development processes.Business Wire BlogVirscio Announces Launch of Pathology and Tissue Pharmacodynamics Services DivisionVirscio launched a Pathology and Tissue Pharmacodynamics Division to complement its preclinical services, led by Dr. Jennifer Cann and Richard Bouffard. The division offers non-GLP, GLP, and GCLP histology and pathology services, including tissue processing, staining, and image analysis. The launch follows investments in advanced microscopy and nonhuman primate capacity.GlobeNewswireVirscio Publishes Data Validating Non-Human Primate Model for Testing Chronic Retinal Neovascularization and Vascular Leakage Drug CandidatesVirscio published data validating a nonhuman primate model for testing drug candidates targeting retinal ischemic and neovascular diseases. The model, induced by DL-aminoadipic acid, recapitulates exudative age-related macular degeneration and diabetic retinopathy in green monkeys. It supports efficacy evaluations of sustained-release strategies and novel therapeutics.GlobeNewswireRxGen Rebrands as Virscio to Reflect Corporate Growth and Enhanced Focus on Comprehensive Suite of Preclinical Research Offerings and CapabilitiesRxGen announced it is rebranding as Virscio to reflect its growth into a leading nonhuman primate preclinical research organization. The new brand highlights its validated disease models and GLP-compliant capabilities across multiple therapeutic areas. The company cites industry-leading study timelines and AAALAC accreditation as key achievements.